Clinical, Immunological and Virological Data, and Lymph Node Cell Mortality in Patients With HIV Infection
| Patient No. . | Age (yr)/sex/Time From Diagnosis (mo) . | CDC Stage . | Antiviral Therapy . | CD4/cmm . | HIV DNA Genomes/100 Cells . | Percent Dead Lymph Node Cells* . | |
|---|---|---|---|---|---|---|---|
| . | . | . | . | . | PBMC . | Lymph Node . | . |
| 1 | 24/M/6 | III | None | 610 | ND | ND | 13.8 |
| 2 | 33/M/6 | III | None | 591 | 0.5 | 2.5 | 10.9 |
| 3 | 29/M/5 | III | None | 560 | 0.08 | 0.05 | 2.1 |
| 4 | 25/M/2 | III | Zidovudine | 495 | 0.04 | 0.6 | 7.9 |
| 5 | 30/F/26 | IV | None | 261 | 0.5 | 4.8 | 18.3 |
| 6 | 28/F/36 | IV | Zidovudine | 150 | 0.08 | 1.3 | 11.5 |
| 7 | 32/M/84 | IV | None | 105 | 2.5 | 3.7 | 14.2 |
| 8 | 27/F/15 | III | Zidovudine | 268 | <0.01 | 0.02 | 10.5 |
| Patient No. . | Age (yr)/sex/Time From Diagnosis (mo) . | CDC Stage . | Antiviral Therapy . | CD4/cmm . | HIV DNA Genomes/100 Cells . | Percent Dead Lymph Node Cells* . | |
|---|---|---|---|---|---|---|---|
| . | . | . | . | . | PBMC . | Lymph Node . | . |
| 1 | 24/M/6 | III | None | 610 | ND | ND | 13.8 |
| 2 | 33/M/6 | III | None | 591 | 0.5 | 2.5 | 10.9 |
| 3 | 29/M/5 | III | None | 560 | 0.08 | 0.05 | 2.1 |
| 4 | 25/M/2 | III | Zidovudine | 495 | 0.04 | 0.6 | 7.9 |
| 5 | 30/F/26 | IV | None | 261 | 0.5 | 4.8 | 18.3 |
| 6 | 28/F/36 | IV | Zidovudine | 150 | 0.08 | 1.3 | 11.5 |
| 7 | 32/M/84 | IV | None | 105 | 2.5 | 3.7 | 14.2 |
| 8 | 27/F/15 | III | Zidovudine | 268 | <0.01 | 0.02 | 10.5 |
CD45+ cells permeable to 7-AAD in lymph node cell suspensions.